Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

(NYSE:HAE) Haemonetics Corporation announced that its financial results for the second quarter of fiscal year 2027, which ended on September 26, 2026, are now available on the company's Investor Relations website at www.haemonetics.com. The company will host a conference call and webcast with investors and analysts to discuss and answer questions about these results at 8:00 a.m. ET on November 5, 2026. Participants can register for the call to receive dial-in details and a personalized PIN, and are recommended to join 10 minutes prior to the event start time. A live webcast will be accessible through the Investor Relations section of the Haemonetics website. A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on November 5, 2026, and will remain accessible for one year via the webcast link. Haemonetics has also posted its Second Quarter Fiscal 2027 Earnings Release and Second Quarter Fiscal 2027 Supplemental Earnings Presentation on its Investor Relations website, which will be referenced during the conference call and webcast. The company’s Apheresis business features proprietary technologies for plasma and blood collectors. The MedSurg business offers Blood Management Technologies and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies. Olga Guyette is Vice President-Investor Relations & Treasury, and David Trenk is Sr. Manager-Investor Relations.

Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System

(NYSE:HAE) Haemonetics Corporation announced that the U.S. Food and Drug Administration (FDA) has approved the PerQseal® Elite vascular closure system for large-bore arterial procedures. This approval expands Haemonetics' portfolio of large-bore closure devices for structural heart and endovascular procedures in the U.S., following its acquisition of Vivasure Medical Limited in January 2026. The PerQseal Elite system is designed to provide sutureless, large-bore vascular closure for procedures performed with 14 – 22F sheaths. The system uses a fully bioabsorbable patch to seal arteriotomies up to 26F from within the vessel, enabling near-instantaneous hemostasis and leaving nothing permanent behind. Physicians can confirm hemostasis while maintaining guidewire access and have the flexibility to reposition or recover the system until implant release. Results from the prospective, single-arm, multicenter ELITE arterial study showed 0% major complications per VARC-3 and a mean time to hemostasis of less than one minute. In 2025, PerQseal Elite received CE Mark approval in Europe for both arterial and venous indications. Jan Hartmann, M.D., Senior Vice President and Chief Medical Officer at Haemonetics, stated that FDA approval is an important milestone in the company's strategy to grow its advanced vascular closure business and that PerQseal Elite could simplify minimally invasive procedures such as TAVR while supporting patient comfort. Professor Nicolas van Mieghem, MD, co-investigator of the ELITE study and interventional cardiologist at ZOL Hospital in Genk, Belgium, commented that PerQseal Elite is easy to adopt, intuitive to use, and integrates well into procedural workflows for large-bore arterial interventions. Haemonetics will present and discuss clinical data related to PerQseal Elite at the Transcatheter Cardiovascular Therapeutics® (TCT) Conference at the end of October.

New Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths

(NYSE: HAE) Haemonetics Corporation announced publication of a study providing new evidence supporting the safety and efficacy of Haemonetics' VASCADE MVP XL venous vascular closure system in large-bore sheath procedures. The retrospective cohort study evaluated real-world outcomes in 1,623 patients who received the VASCADE MVP XL system following large bore (maximum 17F outer diameter (OD) sheaths) venous access electrophysiology procedures. Results demonstrated rapid hemostasis with a median of 2 minutes, a 92.5% same-day discharge rate, and a median time to discharge of 3.5 hours. The study reported a 1.2% overall vascular complication rate with no surgical interventions required. In March 2026, the U.S. Food and Drug Administration (FDA) approved expanded labeling for the VASCADE MVP XL system to include procedures using 10-14F inner diameter (ID) and up to 17F OD procedural sheaths. The VASCADE MVP XL system is approved for use with market-leading technologies for PFA to treat atrial fibrillation and LAAC solutions. The company projects potential benefits associated with the expanded labeling of the VASCADE MVP XL venous vascular closure system.

Martin Madaus Elected to Haemonetics Board of Directors

(NYSE: HAE) Haemonetics Corporation announced that Martin Madaus has been elected to the Company's Board of Directors, effective July 24, 2026. Dr. Madaus brings more than 30 years of leadership experience in the diagnostics and life sciences tools industries. He currently serves as Senior Operating Executive at The Carlyle Group, where since 2019 he has advised on healthcare investments and portfolio company performance. Previously, Dr. Madaus served as Chairman and Chief Executive Officer of Ortho Clinical Diagnostics, Inc. (now QuidelOrtho Corporation), and as Chairman, President and Chief Executive Officer of Millipore Corporation, which was acquired by Merck KGaA in 2010. He also served as President and Chief Executive Officer of Roche Diagnostics North America. Dr. Madaus holds a Doctor of Veterinary Medicine from the University of Munich in Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover in Germany. The company projects that Dr. Madaus' track record of leading complex global organizations, driving operational excellence and creating shareholder value will be invaluable as Haemonetics continues to execute its strategy, expand its leadership across attractive end markets and deliver long-term value for patients, customers and shareholders.

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

(NYSE: HAE) Haemonetics Corporation announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026. Participants can access the call via teleconference after registration, receiving a dial-in number and personalized PIN. A live webcast of the call will be available on Haemonetics' investor relations website. A replay of the conference call and webcast will be available for one year beginning on August 6, 2026 at 11:00 am ET using the provided webcast link. Haemonetics is described as a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. The Company's Apheresis and MedSurg businesses feature proprietary technologies and advanced vascular closure systems.

Haemonetics Updates Financial Reporting Segments

(NYSE: HAE) Haemonetics Corporation announced an update to its reportable segment structure, transitioning from three reportable segments to two. The previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg. Haemonetics will begin reporting financial results under its new reportable segment structure with the first quarter of fiscal year 2027, which commenced on March 29, 2026. The company has posted a supplemental presentation containing recast quarterly historical revenue for fiscal years 2024, 2025, and 2026, as well as a recast of its previously issued fiscal year 2027 revenue guidance. The supplemental presentation is not a reaffirmation or update of the Company's previously issued fiscal year 2027 guidance. Updates, if any, will be provided on the Company's first quarter fiscal year 2027 earnings call. The supplemental presentation is available on the Company's Investor Relations website.

Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Haemonetics Corporation (NYSE: HAE) announced that its financial results for the fourth quarter of fiscal year 2026, which ended March 28, 2026, are now available on the Company's Investor Relations website. The company will host a conference call and webcast with investors and analysts at 8:00 a.m. ET on May 7, 2026, to discuss and answer questions about the results. A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on May 7, 2026, and will remain accessible for one year. Haemonetics has also posted its Fourth Quarter Fiscal 2026 Earnings Release and Supplemental Earnings Presentation online. The company describes itself as a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care.

New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures

Haemonetics Corporation (NYSE: HAE) announced the publication of a new study comparing its VASCADE MVP XL vascular closure system with the VASCADE MVP system for large-bore venous access closure procedures. The study, involving 574 patients, demonstrated VASCADE MVP XL's superior performance, including higher procedural success and 0% bleeding complications. In March 2026, the FDA approved expanded labeling for VASCADE MVP XL to include procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths. Additional clinical data and imaging-based assessments were published and will be presented at Heart Rhythm 2026. This matters to investors as it highlights regulatory progress, clinical validation, and potential market expansion for Haemonetics' products.